Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Minor and James Medical, PLLC
mi
from
Seattle, WA
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Minor and James Medical, PLLC
mi
from
Seattle, WA
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Camc Institute
mi
from
Charleston, WV
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Camc Institute
mi
from
Charleston, WV
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Center for Neurological Disorders
mi
from
Milwaukee, WI
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Center for Neurological Disorders
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Servicio de Neurologia
mi
from
Buenos Aires,
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Servicio de Neurologia
mi
from
Buenos Aires,
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
mi
from
Phoenix, AZ
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
University of Southern California
mi
from
Los Angeles, CA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
California Pacific Medical Center
mi
from
San Francisco, CA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
University of Florida Gainesville
mi
from
Gainesville, FL
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
University of Florida Gainesville
mi
from
Gainesville, FL
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Miami Children's Hospital
mi
from
Miami, FL
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Miami Children's Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Medical College of Georgia at Georgia Regents University
mi
from
Augusta, GA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Medical College of Georgia at Georgia Regents University
mi
from
Augusta, GA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center / Epilepsy Center
mi
from
Chicago, IL
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center / Epilepsy Center
mi
from
Chicago, IL
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Indiana University
mi
from
Indianapolis, IN
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Via Christi Comprehensive Epilepsy Center
mi
from
Wichita, KA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Via Christi Comprehensive Epilepsy Center
mi
from
Wichita, KA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Louisiana State University Epilepsy Center of Excellence
mi
from
New Orleans, LA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Louisiana State University Epilepsy Center of Excellence
mi
from
New Orleans, LA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Saint Barnabas Medical Center
mi
from
Livingston, NJ
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Saint Barnabas Medical Center
mi
from
Livingston, NJ
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Weill Medical College of Cornell University
mi
from
New York, NY
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Columbia University / Columbia Presbyterian Medical Center
mi
from
New York, NY
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Columbia University / Columbia Presbyterian Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
University of Rochester
mi
from
Rochester, NY
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
University of Virginia
mi
from
Charlottesville, VA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center
mi
from
Seattle, WA
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated:  12/31/1969
George Washington University
mi
from
Washington,
RNS® System LTT Study
RNS® System Long-term Treatment (LTT) Clinical Investigation
Status: Enrolling
Updated: 12/31/1969
George Washington University
mi
from
Washington,
Click here to add this to my saved trials
Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study
Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study
Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis
A Placebo-controlled Double Blind Crossover Trial of Acetylsalicylic Acid as a Pre-treatment for Exercise in Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center, MS Center
mi
from
New York, NY
Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis
A Placebo-controlled Double Blind Crossover Trial of Acetylsalicylic Acid as a Pre-treatment for Exercise in Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center, MS Center
mi
from
New York, NY
Click here to add this to my saved trials
Gilenya's Impact on Cognitive Function and Thalamic Volumes
Impact of Gilenya on Cognitive Function and Thalamic Volume Measured by 7 Tesla MRI in Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Gilenya's Impact on Cognitive Function and Thalamic Volumes
Impact of Gilenya on Cognitive Function and Thalamic Volume Measured by 7 Tesla MRI in Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Validity and Inter-Rater Reliability of a Novel Bedside Referral Tool for Spasticity
Validity and Inter-Rater Reliability of a Novel Bedside Referral Tool for Spasticity
Status: Enrolling
Updated:  12/31/1969
Tennessee State Veterans' Homes
mi
from
Murfreesboro, TN
Validity and Inter-Rater Reliability of a Novel Bedside Referral Tool for Spasticity
Validity and Inter-Rater Reliability of a Novel Bedside Referral Tool for Spasticity
Status: Enrolling
Updated: 12/31/1969
Tennessee State Veterans' Homes
mi
from
Murfreesboro, TN
Click here to add this to my saved trials
Using Telemedicine to Improve Spasticity Diagnosis Rates
Using Telemedicine to Improve Spasticity Diagnosis Rates
Status: Enrolling
Updated:  12/31/1969
Tennessee State Veterans' Homes
mi
from
Murfreesboro, TN
Using Telemedicine to Improve Spasticity Diagnosis Rates
Using Telemedicine to Improve Spasticity Diagnosis Rates
Status: Enrolling
Updated: 12/31/1969
Tennessee State Veterans' Homes
mi
from
Murfreesboro, TN
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Dasotraline (2mg) in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety in a Laboratory Classroom Setting
Status: Enrolling
Updated:  12/31/1969
AVIDA, Inc.
mi
from
Newport Beach, CA
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Dasotraline (2mg) in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety in a Laboratory Classroom Setting
Status: Enrolling
Updated: 12/31/1969
AVIDA, Inc.
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Dasotraline (2mg) in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety in a Laboratory Classroom Setting
Status: Enrolling
Updated:  12/31/1969
Meridien Research
mi
from
Bradenton, FL
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Dasotraline (2mg) in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety in a Laboratory Classroom Setting
Status: Enrolling
Updated: 12/31/1969
Meridien Research
mi
from
Bradenton, FL
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Dasotraline (2mg) in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety in a Laboratory Classroom Setting
Status: Enrolling
Updated:  12/31/1969
Meridien Research, Inc.
mi
from
Maitland, FL
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Dasotraline (2mg) in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety in a Laboratory Classroom Setting
Status: Enrolling
Updated: 12/31/1969
Meridien Research, Inc.
mi
from
Maitland, FL
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Dasotraline (2mg) in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety in a Laboratory Classroom Setting
Status: Enrolling
Updated:  12/31/1969
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Dasotraline (2mg) in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety in a Laboratory Classroom Setting
Status: Enrolling
Updated: 12/31/1969
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Dasotraline (2mg) in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety in a Laboratory Classroom Setting
Status: Enrolling
Updated:  12/31/1969
Bayou City Research, Ltd.
mi
from
Houston, TX
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Dasotraline (2mg) in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety in a Laboratory Classroom Setting
Status: Enrolling
Updated: 12/31/1969
Bayou City Research, Ltd.
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Dasotraline (2mg) in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety in a Laboratory Classroom Setting
Status: Enrolling
Updated:  12/31/1969
Qps-Mra, Llc
mi
from
South Miami, FL
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Dasotraline (2mg) in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety in a Laboratory Classroom Setting
Status: Enrolling
Updated: 12/31/1969
Qps-Mra, Llc
mi
from
South Miami, FL
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Dasotraline (2mg) in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety in a Laboratory Classroom Setting
Status: Enrolling
Updated:  12/31/1969
South Shore Psychiatric Services PC
mi
from
Hingham, MA
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Dasotraline (2mg) in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety in a Laboratory Classroom Setting
Status: Enrolling
Updated: 12/31/1969
South Shore Psychiatric Services PC
mi
from
Hingham, MA
Click here to add this to my saved trials